News headlines about Prana Biotechnology (NASDAQ:PRAN) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Prana Biotechnology earned a news impact score of 0.06 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 47.307765935831 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several brokerages recently issued reports on PRAN. ValuEngine raised Prana Biotechnology from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded Prana Biotechnology from a “sell” rating to a “hold” rating in a report on Wednesday, May 23rd.
Prana Biotechnology traded up $0.04, reaching $1.98, during trading hours on Monday, Marketbeat reports. 2,000 shares of the company’s stock were exchanged, compared to its average volume of 28,620. Prana Biotechnology has a twelve month low of $1.75 and a twelve month high of $3.79. The company has a market cap of $17.26 million, a P/E ratio of -3.09 and a beta of -0.12.
Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases.
Receive News & Ratings for Prana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.